Xencor Inc. Common Stock (XNCR) fair value

ACCE thesis

Xencor develops antibody therapeutics built on its proprietary XmAb engineering platform, with its lead clinical programs targeting oncology and autoimmune disease. Its advantage rests on that platform, which lets the company design bispecific and Fc-engineered antibodies and license them to larger drug makers for upfront and milestone payments. Revenue is growing 17.5%, but the business is still deeply loss-making, with a -72.4% operating margin and a -143.6% gross margin, so the thesis depends on partnered milestones and pipeline readouts arriving before cash runs thin. At a 68x forward P/E on a company with negative earnings, the market is pricing in a successful clinical outcome that the reported numbers do not yet show. The 48/100 score and absence from any index suggest the name is not screening well on fundamentals, so the case for a deeper look rests on the pipeline data, not the current financials.